NDAINTRAVENOUSPOWDER
Approved
Jun 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
6/8 — Strong
KENGREAL (cangrelor) by Chiesi is p2y12 receptor antagonists [moa]. Approved for p2y12 platelet inhibitor [epc]. First approved in 2015.
Drug data last refreshed 3d ago
Mechanism of Action
P2Y12 Receptor Antagonists
Pharmacologic Class:
P2Y12 Platelet Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (9)
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
Started Jun 2021
128 enrolled
ST-elevation Myocardial Infarction
Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock
Started May 2021
303 enrolled
Acute Myocardial Infarction
Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor
Started Jan 2021
17 enrolled
Coronary Artery Disease
ARCANGELO (itAlian pRospective Study on CANGrELOr)
Started Oct 2020
1,005 enrolled
Acute Coronary Syndrome
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
Started Oct 2019
5,050 enrolled
Myocardial Infarction
Worked on KENGREAL at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.